story of the week
Nivolumab Results in High Rate of Response in Refractory Classical Hodgkin's Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Nivolumab for Classical Hodgkin's Lymphoma After Failure of Both Autologous Stem-Cell Transplantation and Brentuximab Vedotin: A Multicentre, Multicohort, Single-Arm Phase 2 Trial
Lancet Oncol 2016 Jul 20;[EPub Ahead of Print], A Younes, A Santoro, M Shipp, PL Zinzani, JM Timmerman, S Ansell, P Armand, M Fanale, V Ratanatharathorn, J Kuruvilla, JB Cohen, G Collins, KJ Savage, M Trneny, K Kato, B Farsaci, SM Parker, S Rodig, MG Roemer, AH Ligon, A EngertFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.